A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms INEXAS
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 10 Mar 2017 According to a Synairgen media release, outcomes are expected during the first half of 2017.
- 12 Oct 2016 According to a Synairgen media release, full results from this trial areexpected in the first quarter of 2017.